Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

被引：0
|
作者：
Huang, M. J. [1 ,2 ]
Yu, M. [1 ,2 ]
Gong, Y. L. [2 ,3 ]
Li, Y. Y. [2 ]
Liu, Y. M. [2 ]
Peng, F. [2 ]
Yu, Y. [2 ]
Xiu, W. G. [2 ]
Wang, Y. S. [2 ,4 ]
Zou, B. W. [2 ]
Fan, H. [5 ]
Zhong, L. Q. [6 ]
Liu, T. Q. [7 ]
Wang, X. F. [8 ]
Xu, Y. [2 ]
Zhou, L. [2 ]
Lu, Y. [1 ,3 ,9 ]
机构：
[1] Sichuan Univ, West China Hosp, Div Thorac Tumor Multimodal Treatment, Ctr Canc, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Radiat Oncol, Ctr Canc, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Clin Res, Chengdu, Peoples R China
[5] Peoples Hosp Leshan, Leshan, Peoples R China
[6] Yibin Second Peoples Hosp, Yibin, Peoples R China
[7] Hosp Shimian Cty, Yaan, Peoples R China
[8] Sichuan Sci City Hosp, Chengdu, Peoples R China
[9] Sichuan Univ, West China Hosp, Lab Clin Cell Therapy, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; icotinib; central nervous system metastases;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.05
引用
下载
收藏
页码：S146 / S146
页数：1
相关论文
共 50 条
  • [31] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
    Hafner, Susanne
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [32] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
    Susanne Hafner
    Signal Transduction and Targeted Therapy, 6
  • [33] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [34] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [35] Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S396 - S396
  • [36] Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
    Zhu, Viola Weijia
    Bestvina, Christine M.
    Lopes, Gilberto
    Hamm, John Turner
    Johnson, Melissa Lynne
    Lammers, Philip Edward
    Le, Xiuning
    Marathe, Omkar
    Raez, Luis E.
    Rao, Suman
    Sabari, Joshua K.
    Scheff, Ronald J.
    Tapan, Umit
    Thompson, Jonathan Robert
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Brutlach, Sabine
    Smit, Egbert F.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
    Wang, P.
    Li, Y.
    Lv, D.
    Ding, L.
    Hong, W.
    Han-Zhang, H.
    Lin, J.
    Zhou, J.
    Wang, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S599
  • [38] First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation
    Shi, Yuankai
    Wang, Lin
    Han, Baohui
    Li, Wei
    Yu, Ping
    Liu, Yunpeng
    Ding, Cuimin
    Song, Xia
    Ma, Zhiyong
    Ren, Xinling
    Feng, Jifeng
    Zhang, Helong
    Chen, Gongyan
    Wu, Ning
    Han, Xiaohong
    Yao, Chen
    Song, Yong
    Zhang, Shucai
    Ding, Lieming
    Tan, Fenlai
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S205 - S206
  • [39] Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial
    Lin, G.
    Chu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S446 - S446
  • [40] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
12345